Connect Biopharma Holdings Ltd
Close on Oct 19, 2026
- Market cap
- $56.58M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | After market close | $2.80M | $-0.27 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | Before market open | $200.00K | $-0.34 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 31, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | Before market open | $48.00K | $-0.23 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | Before market open | – | $-0.19 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | Before market open | – | – | – |
Press releases
Announcements Connect Biopharma filed with the SEC
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CBP-201-207 Rademikibart Add-on Treatment of an Acute COPD Exacerbation Preliminary Results (Seabreeze STAT COPD) Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
CBP-201-206 Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma) Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Connect Biopharma Announces $20.2 Million Private Placement Financing
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Connect Biopharma Reports Third Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Connect Biopharma’s Exclusive Licensee in China, Simcere Pharmaceutical, Announced Submission of its New Drug Application for Rademikibart for the Treatment of Atopic Dermatitis in China
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Connect Biopharma Reports 2024 Full-Year Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
EXCLUSIVE LICENSE AND COLLABORATION AGREEMENT
EX-99.1 to Form 6-K
Connect Biopharma Reports Full Year 2022 Financial Results
EX-99 to Form 6-K
Connect Biopharma Provides Business and
EX-99.1 to Form 6-K
Connect Biopharma Reports First Half 2022 Financial Results
EX-99.1 to Form 6-K
CBP-307 Top-line Phase 2 Results in
EX-99.2 to Form 6-K
Connect Biopharma Reports Full Year 2021 Financial Results
EX-99.1 to Form 6-K